ArticleAntimicrobial agents and chemotherapy2010
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.Antimicrobial agents and chemotherapy · 2013Trial
- Identification of cell wall binding domains and repeats inBiochemistry and biophysics reports · 2024Article
- Recent development and fighting strategies for lincosamide antibiotic resistance.Clinical microbiology reviews · 2024Review
- Serotypes and Vaccine Coverage ofPathogens (Basel, Switzerland) · 2020Article
- Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.Communications biology · 2020Article
- Antibiotic Prophylaxis for Children With Sickle Cell Anemia.Pediatrics · 2018Article
- Treatment of Community-Acquired Pneumonia: Are All Countries Treating Children in the Same Way? A Literature Review.International journal of pediatrics · 2017Review
- Clinical, Paraclinical, and Antimicrobial Resistance Features of Community-Acquired Acute Bacterial Meningitis at a Large Infectious Diseases Ward in Tehran, Iran.Iranian journal of pharmaceutical research : IJPR · 2016Article
- Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.Antimicrobial agents and chemotherapy · 2014Article
- Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.Antimicrobial agents and chemotherapy · 2014Article
- In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.Antimicrobial agents and chemotherapy · 2014Article
- Review
- Severe community-acquired pneumonia.Critical care clinics · 2013Review
- Review
- Pneumonia Due to Drug-Resistant Streptococcus pneumoniae.Current infectious disease reports · 2012Article
- In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.Antimicrobial agents and chemotherapy · 2012Article
- Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.Infection and drug resistance · 2012Article
- Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Therapeutics and clinical risk management · 2012Article
- In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Antimicrobial agents and chemotherapy · 2011Article
- Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Clinical medicine reviews in therapeutics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 microg/ml and the MIC(90)s being <0.008 to 0.25 microg/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.